智通财经APP获悉，制药巨头礼来(LLY.US)周五公布了收购基因治疗公司Adverum Biotechnologies(ADVM.US)及其主要基因治疗候选药物Ixo-vec ...

Adverum Biotechnologies (ADVM) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

日前，Adverum Biotechnologies公司宣布，其主打基因疗法ADVM-022获得欧洲药品管理局（EMA）的PRIME药品认定，用于治疗湿性年龄相关性黄斑变性（AMD）。ADVM-022是一款玻璃体内注射治疗湿性AMD的一次性基因疗法。 湿性AMD是AMD的严重形式，影响大约10%的AMD患者。它是65岁 ...

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) is among the best fundamentally strong penny stocks to buy right now. During the first quarter, Trexquant Investment LP reduced its stake in Adverum ...

Adverum will sell the shares at a price per share of $1.20, representing a premium of approximately 20% to its stock’s 30-day volume-weighted average price, and the financing is expected to close on ...

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).

TD Cowen analyst Joseph Thome maintained a Buy rating on Adverum Biotechnologies (ADVM – Research Report) yesterday. The company’s shares closed yesterday at $7.54. Thome covers the Healthcare sector, ...

Hedge funds and other investment firms run by legendary investors like Israel Englander and Ray Dalio are entrusted to manage billions of dollars of accredited investors’ money because they are ...

Beyond, ADVM-022, we are focused on developing a pipeline of novel gene therapies. Our industry-leading AAV platform provides us with a number of compelling options for expansion and we look forward ...